Last reviewed · How we verify
NRG Oncology — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
6 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Gonadotrophin Releasing Hormone | Gonadotrophin Releasing Hormone | phase 3 | GnRH agonist | GnRH receptor | Oncology | |
| Adjuvant Chemotherapy + Ovarian Function Suppression | Adjuvant Chemotherapy + Ovarian Function Suppression | phase 3 | Combination regimen (chemotherapy + endocrine therapy) | Oncology | ||
| Ovarian Function Suppression + Aromatase Inhibitor | Ovarian Function Suppression + Aromatase Inhibitor | phase 3 | Combination endocrine therapy (GnRH agonist/antagonist + aromatase inhibitor) | GnRH receptor (ovarian suppression component) and aromatase enzyme (AI component) | Oncology |
Therapeutic area mix
- Oncology · 5
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AbbVie (prior sponsor, Abbott) · 1 shared drug class
- Abbott · 1 shared drug class
- Asan Medical Center · 1 shared drug class
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
- Bayer · 1 shared drug class
- Bristol-Myers Squibb · 1 shared drug class
- Centre Oscar Lambret · 1 shared drug class
- AbbVie · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for NRG Oncology:
- NRG Oncology pipeline updates — RSS
- NRG Oncology pipeline updates — Atom
- NRG Oncology pipeline updates — JSON
Cite this brief
Drug Landscape (2026). NRG Oncology — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nrg-oncology. Accessed 2026-05-16.